title: The use of DDAVP in children with bleeding disorders.
abstract: Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) has been used in children with von Willebrand disease (VWD) and Hemophilia A for almost 35 years. This treatment has substantially lowered the number of children exposed to human plasma derived products, with a good safety profile, and at very low cost. The response to DDAVP has been shown to be associated with age, baseline factor level, and genetic mutations. A DDAVP challenge test is recommended. DDAVP has also been used to prevent and treat bleeding episodes in children with platelet function defects and other disorders associated with bleeding tendency.
authors.affiliation: The Pediatric Hematology/Oncology Department, Hadassah Hebrew-University Hospital, Jerusalem, Israel.
authors.forename: Tal
authors.initials: T
authors.lastname: Ben-Ami
authors.forename: Shoshana
authors.initials: S
authors.lastname: Revel-Vilk
mesh_terms: D025861:Blood Coagulation Disorders, Inherited / Q000188:drug therapy*; D001792:Blood Platelets / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D006487:Hemostasis; D006801:Humans; D010979:Platelet Function Tests; D014842:von Willebrand Diseases / Q000188:drug therapy*
chemical_list: D003894:Deamino Arginine Vasopressin